INTRODUCTION {#s1}
============

Infection by hepatitis B virus (HBV) appears under different forms of evolution, ranging from the asymptomatic and self-limited infection to the chronic state, which can develop into chronic hepatitis, cirrhosis, and hepatocellular carcinoma[@b1]. So far, factors that determine the variable outcomes of HBV infection are little known. Besides pathogenesis of virus, environment factors, ethnic differences and genetic susceptibility have also been reported to have an effect on the progression of this liver disease[@b2]. Recently, a number of studies have shown that genetic polymorphisms of cytokines have a correlation with the outcomes of HBV infection[@b3],[@b4]. However, controversies exist among similar studies.

Interferon-γ (*IFN-γ*) is known as a Th1 cytokine, and plays a pivotal role in defending against the invasion of intracellular pathogens and the induction of an immune-mediated inflammatory response[@b5]. During viral infections, the expression pattern of cytokines is changed and *IFN-γ* level is increased[@b6]. Interestingly, a single nucleotide polymorphism (SNP) located in the *IFN-γ* gene intron (at position +874) was involved in transcriptional regulation of *IFN-γ*[@b7] and HBV susceptibility[@b8]. Some studies demonstrated that patients carrying rs2430561 AA genotype in the *IFN-γ* gene had a high risk of susceptibility to chronic infection of HBV[@b9]-[@b11], while Cheong et al.[@b12] observed no significant difference in susceptibility risk.

Interleukin 28B (*IL28B*, interferon-λ3 \[IFN-λ3\]) is another cytokine involved in the host immune response to virus infection, such as hepatitis C virus (HCV) and HBV. There also had been several studies on the relationship between chronic HBV infection, HBV clearance and genetic polymorphism of the *IL28B* gene rs12979860 C/T. However, the results are inconsistent. For instance, Ren et al.[@b13] found that the frequency of CC homozygosity was significantly higher in healthy controls than that in chronic hepatitis B patients, but other studies did not find such difference[@b14],[@b15].

It was reported that estrogen could directly activate the promoter of *IFN-γ* and this effect was mediated by estrogen receptors (ERs, *ERα* and ERβ)[@b16]. The expression and function of ER might be influenced by its own variation and thus modulate diverse pathologies correlated with prognosis and survival of chronic hepatopathy[@b17],[@b18]. Previous studies[@b19]-[@b21] reported an association of *ER* polymorphisms with susceptibility to chronic HBV infection and other chronic hepatic diseases. Deng et al.[@b19] found that, as a haplotype-tagging SNP, *ERα* rs2077647 T/C genotype (previous reported c.30T \> C, exon 1) had an influence on susceptibility to persistent HBV infection and HBV-related hepatocellular carcinoma. It was also observed that the relative messenger RNA levels of the at-risk C allele of rs2077647 were consistently higher than those of the T allele in the heterozygous cells[@b22]. Therefore, it is rational to consider that *ERα* may be a biological candidate susceptibility gene for chronic HBV infection.

To our knowledge, the recent results about the associations of *IFN-γ* rs2430561 T/A, *IL28B* rs12979860 C/T and *ERα* rs2077647 T/C gene polymorphisms with the outcomes of HBV infection in many studies are inconsistent. Therefore, to assess the associations between these SNPs and the outcomes of HBV infection, we performed a meta-analysis of all the published observational studies.

MATERIALS AND METHODS {#s2}
=====================

Publication search {#s2a}
------------------

PubMed (<http://www.ncbi.nlm.-nih.gov/pubmed>), web of science (<http://www>. thomsonscientific.com.cn/), CNKI (China National Knowledge Infrastructure) (<http://epub.cnki.net/kns/default.htm>) and Chinese Biomedicine databases (<http://www.sinomed.ac.cn>) were searched (the last search was updated in July 2013) using the search terms: 'hepatitis B' or 'HBV', 'polymorphism' or 'mutation' or 'variant', 'interferon-gamma' or 'interferon γ' or 'interleukin 28B' or 'estrogen receptor alpha' or 'estrogen receptor α'. The results were supplemented with manual searches of references of final published articles. Review articles, editorials or conference abstracts were excluded. When more than one of the same patient population was included in several publications, only the most recent or complete study was used in this meta-analysis. A flow diagram of the study selection process is shown in [***Fig. 1***](#f01){ref-type="fig"}.

![Flow diagram of studies included in the meta-analysis.\
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Inclusion and exclusion criteria {#s2b}
--------------------------------

Inclusion criteria were as follows: (1) patients with no detectable HBV infection were defined as healthy controls (HCs); patients whose serum HBV surface antigen (HBsAg) was negative but HBV surface antibody (anti-HBs) and/or HBV core antibody (anti-HBc) were positive were defined as self-limiting infection controls (SLCs); patients who had been positive for HBsAg or HBV DNA for at least 6 months were included as persistent HBV infection cases (PIs); (2) design type of the study was a case-control study; (3) the study aimed to examine the relationship between the *IFN-γ* rs2430561 or *IL28B* rs12979860 or *ERα* rs2077647 T/C polymorphisms and clearance and/or susceptibility of persistent HBV infection; (4) the study provided sufficient data for examining an odds ratio (OR) with 95% confidence interval (CI); (5) the patients recruited in the studies had not received prior HBV-related treatment. Exclusion criteria were as follows: (1) the study fitted no diagnosis criteria; (2) the study was not a case-control study; (3) the study reported no usable data.

Data extraction {#s2c}
---------------

Two investigators (ST and JW) extracted information from all eligible publications independently according to the inclusion criteria listed above. Disagreements were resolved by discussion. The following information was extracted from each publication, including name of the first author, year of publication, country/region of the first or corresponding author, ethnicity, number of cases and controls, genotyping methods, and polymorphisms of *IFN-γ* rs2430561, *IL28B* rs12979860 or *ERα* rs2077647. If the information mentioned in this section and above section was unavailable in relevant articles, a request was sent to corresponding author for additional data.

Statistical analysis {#s2d}
--------------------

The statistical analysis was conducted using Stata 10.0 (StataCorp, College Station, TX, USA). At the beginning of the analysis, we assessed Hardy-Weinberg equilibrium (HWE) in the controls for each study using Chi-square test (*P* ≤ 0.05 was considered as a deviation from HWE). Then, the risks (ORs, and 95% CIs) of persistent HBV infection associated with *IFN-γ* rs2430561, *IL28B* rs12979860 and *ERα* rs2077647 were estimated for each study based on extracted genotype data. We also carried out stratified analyses by ethnicity (Asian and Caucasian) and sources (hospital-based and population-based). Moreover, sensitivity analysis was performed to assess the stability of results while omitting the study not in HWE, one at a time. Q-statistic and I^2^ statistic were performed to evaluate statistical heterogeneity. When *P* \> 0.10 for Q-statistic or I^2^ ≤ 50%, heterogeneity was considered to be absent and a fixed effects model was used; otherwise, a random effects model was used. Several methods were used to assess the potential for publication bias, including visual inspection of asymmetry in funnel plots, Begg\'s test and Egger\'s test. *P* ≤ 0.05 was considered to be representative of significant publication bias.

RESULTS {#s3}
=======

Characteristics of studies {#s3a}
--------------------------

A total of 24 relevant studies ([***Table 1***](#t01){ref-type="table"}) evaluating *IFN-γ* rs2430561 T/A, *IL28B* rs12979860 C/T and *ERα* rs2077647 T/C SNPs were found in our search, and the characteristics of each study are summarized according to the polymorphisms in [***Table 1***](#t01){ref-type="table"}. The countries in which these studies were carried out include China, South Korea, Brazil, Iran, Spain, United States, Italy and Romania. Eighteen studies were on Asians, 5 on Caucasians and 1 on Brazilians, which included mixed ancestry of Caucasians (European), African and "other" (Amerindian). Sixteen of the 24 eligible studies were hospital-based case-control studies while the remaining 8 were population-based. The distribution of genotypes in the controls of all studies was in agreement with HWE except for 4 studies[@b10],[@b11],[@b13],[@b19].

###### Characteristics and *IFN-γ* rs2430561, *IL28B* rs12979860 and *ERα* rs2077647 polymorphism genotype distributions in studies included in the meta-analysis

  Author                  Year/countries                 Ethnicity                   Sources               SNPs            Genotypes          Sample size           HWE in control                               
  -------------------- -------------------- ----------------------------------- ------------------ -------------------- ---------------- ---------------------- ----------------------- ------------------------ ---------------------------------------
  Zhang PA[@b11]            2006/China                     Asian                  Hospital-based    *IFN-γ* rs2430561    TT/TA/AAT vs A    17/31/8765 vs 205      23/39/10385 vs 245       21/28/18270 vs 392     0.00 [a](#nt101){ref-type="table-fn"}
  Gao QJ[@b10]              2009/China                     Asian                 Population-based   *IFN-γ* rs2430561    TT/TA/AAT vs A     7/53/1467 vs 81               \-                9/35/2553 vs 85                       0.00
  Cheong JY[@b12]        2006/South Korea                  Asian                  Hospital-based    *IFN-γ* rs2430561    TT/TA/AAT vs A            \-              3/47/15153 vs 347       5/94/314104 vs 722                     0.76
  Ribeiro CSS[@b33]        2007/Brasil       European, African and Amerindians    Hospital-based    *IFN-γ* rs2430561    TT/TA/AAT vs A     3/23/1429 vs 51               \-                6/12/1224 vs 36                       0.12
  Arababadi MK[@b34]        2011/ Iran                   Caucasian               Population-based   *IFN-γ* rs2430561    TT/TA/AAT vs A    25/47/2897 vs 103              \-                14/25/1853 vs 61                      0.55
  Wu JM[@b35]               2008/China                     Asian                  Hospital-based    *IFN-γ* rs2430561    TT/TA/AAT vs A            \-               23/30/776 vs 44        32/50/36114 vs 122                     0.55
  Zhi LT[@b36]              2006/China                     Asian                  Hospital-based    *IFN-γ* rs2430561    TT/TA/AAT vs A            \-             7/108/351122 vs 810      6/87/19399 vs 473                      0.69
  Peng XM[@b37]             2007/China                     Asian                  Hospital-based    *IFN-γ* rs2430561    TT/TA/AAT vs A            \-              2/33/6537 vs 163        4/89/24797 vs 583                      0.35
  Liu MQ[@b8]               2006/China                     Asian                  Hospital-based    *IFN-γ* rs2430561        T vs A            253 vs 291                 \-                    101/261                         \>0.05^b^
  Luz MC[@b14]              2012/Spain                   Caucasian                Hospital-based    *IL28B* rs12979860   CC/CT/TTC vs T            \-               22/21/665 vs 33         29/17/375 vs 23                       0.78
  Martin MP[@b15]       2010/United States               Caucasian               Population-based   *IL28B* rs12979860   CC/CT/TTC vs T            \-            157/175/52489 vs 279      99/94/33292 vs 160                     0.77
  Shi XD[@b32]              2011/China                     Asian                  Hospital-based    *IL28B* rs12979860   CC/CT/TTC vs T      19/0/038 vs 0                \-               114/23/0251 vs 23                    \>0.05^b^
  Ren S[@b13]               2012/China                     Asian                  Hospital-based    *IL28B* rs12979860   CC/CT/TTC vs T      43/4/090 vs 4          33/7/373 vs 13         177/46/16400 vs 78     0.01 [a](#nt101){ref-type="table-fn"}
  Fabris C[@b38]            2010/Italy                   Caucasian               Population-based   *IL28B* rs12979860   CC/CT/TTC vs T   164/145/35473 vs 215            \-                36/35/4107 vs 43                      0.72
  Chen J[@b39]              2012/China                     Asian                 Population-based   *IL28B* rs12979860   CC/CT/TTC vs T    213/29/2455 vs 33              \-             1043/152/102238 vs 172                   0.37
  Peng LJ[@b40]             2011/China                     Asian                 Population-based   *IL28B* rs12979860      CC/CT+TT               \-                   206/20                   574/77                         \>0.05^b^
  Li WY[@b28]               2011/China                     Asian                  Hospital-based    *IL28B* rs12979860      CC/CT+TT             179/24                 180/23                   178/25                         \>0.05^b^
  Lee DH[@b41]              2013/Korea                     Asian                  Hospital-based    *IL28B* rs12979860       C vs T            381 vs 23               973 vs 62                   \-                           \>0.05^b^
  Deng GH[@b19]             2004/China                     Asian                  Hospital-based     *ERα* rs2077647     TT/TC/CCT vs C            \-            246/388/108880 vs 604   528/595/1481651 vs 891                   0.02
  Zhou N[@b42]              2009/China                     Asian                  Hospital-based     *ERα* rs2077647     TT/TC/CCT vs C     23/35/2281 vs 79              \-               96/57/19249 vs 95                      0.26
  Li ZX[@b43]               2007/China                     Asian                  Hospital-based     *ERα* rs2077647     TT/TC/CCT vs C     21/33/1675 vs 65              \-               73/49/15195 vs 79                      0.66
  Shan KR[@b44]             2010/China                     Asian                 Population-based    *ERα* rs2077647     TT/TC/CCT vs C     26/26/878 vs 42               \-                20/23/263 vs 27                       0.71
  Long L[@b45]              2009/China                     Asian                 Population-based    *ERα* rs2077647     TT/TC/CCT vs C    71/79/36221 vs 151             \-               70/94/7234 vs 108                      0.10
  Anghel A[@b46]           2010/Romania                  Caucasian                Hospital-based     *ERα* rs2077647     TT/TC/CCT vs C     48/57/9153 vs 75              \-                  4/7/115 vs 9                        0.16

HWE was calculated by the merged data of healthy controls and self-limiting controls. ^b^ *P* value for HWE was extracted from original publication.

*Abbreviations:* SNPs, single nucleotide polymorphisms; HC, healthy control; SLC, self-limiting control; PI, persistent infection; HWE, Hardy-Weinberg equilibrium.

Association of individual polymorphisms with susceptibility to persistent HBV infection {#s3b}
---------------------------------------------------------------------------------------

We compared persistent HBV infection cases with healthy controls to discover the relation of *IFN-γ* rs2430561 T/A, *IL28B* rs12979860 C/T and *ERα* rs2077647 T/C SNPs to persistent HBV infection susceptibility. As shown in [***Table 2***](#t02){ref-type="table"}, the *IFN-γ* rs2430561 T allele was associated with significantly reduced persistent HBV infection risk (T *vs.* A: OR, 0.690; 95% CI \[0.490, 0.971\]; *P*  =  0.033) ([***Fig. 2A***](#f02){ref-type="fig"}), while the *ERα* rs2077647 T allele significantly increased the risk of persistent HBV infection (T *vs.* C: OR, 1.678; 95% CI \[1.212, 2.323\]; *P*  =  0.002). In addition, the results of TT *vs.* CC and CC *vs.* CT+TT implied that *ERα* rs2077647 CC might play a role in protecting individuals against HBV persistence (TT *vs.* CC: OR, 4.109; 95% CI, \[2.609, 6.473\]; *P* \< 0.001; CC *vs.* CT+TT: OR, 0.301; 95% CI, \[0.199, 0.454\]; *P* \< 0.001) ([***Fig. 2C***](#f02){ref-type="fig"} and [D](#f02){ref-type="fig"}, respectively). No evidence of a relationship between *IL28B* rs12979860 C/T and persistent HBV infection risk was observed in all comparison models.

![Forest plots of associations between polymorphisms and outcomes of HBV infection.\
A: *IFN* rs2430561 T *vs.* A in comparison of PI and HC; B: *IFN* rs2430561 TT *vs.* AA in comparison of PI and SLC; C: *ERα* rs2077647 TT *vs.* CC in comparison of PI and HC; D: *ERα* rs2077647 CC *vs.* (TT+TC) in comparison of PI and HC. HC: healthy control; SLC: self-limiting control; PI: persistent infection.](jbr-28-06-484-g002){#f02}

###### Quantitative data synthesis of individual polymorphisms, persistent hepatitis B virus infection cases versus healthy controls

  SNPs                          Comparison                      n      OR (95% CI)     Homogeneity    Publication bias                                  
  ------------ --------------------------------------------- ------- --------------- --------------- ------------------ ------- ------- ------- ------- ------------------------------------
  *IFN-γ*                           T/A                         5         0.690       (0.490,0.971)       0.033\*        12.58   0.014   68.2    0.806                 0.079
  rs2430561                        TT/AA                        4         0.779       (0.487,1.245)        0.296         2.54    0.468    0.0    1.000                 0.798
                                TT/(TA+AA)                      4         0.854       (0.554,1.318)        0.477         1.57    0.665    0.0    1.000                 0.032
  AA/(TA+TT)                         4                        1.048   (0.392,2.801)       0.926            24.80         0.000   87.9    1.000   0.256  
  *IL28B*                           C/T                         4         0.698       (0.373,1.305)        0.260         10.26   0.016   70.8    1.000                 0.316
  rs12979860      CC/TT [a](#nt103){ref-type="table-fn"}        3         0.980       (0.476,2.018)        0.956         3.50    0.174   42.9    1.000   \-[b](#nt104){ref-type="table-fn"}
                                CC/(CT+TT)                      5         0.821       (0.630,1.069)        0.143         7.33    0.120   45.4    1.000                 0.293
                TT/(CC+CT) [a](#nt103){ref-type="table-fn"}     3         0.921       (0.453,1.873)        0.821         3.27    0.195   38.9    1.000   \-[b](#nt104){ref-type="table-fn"}
  *ERα*                             T/C                         5         1.678       (1.212,2.323)       0.002\*        9.80    0.044   59.2    0.806                 0.125
  rs2077647                       TT/ CC                        5         4.109       (2.609,6.473)       0.000\*        2.66    0.616    0.0    0.462                 0.079
                                TT/(TC+CC)                      5         1.595       (0.929,2.738)        0.091         13.53   0.009   70.4    0.806                 0.968
                                CC/(TT+TC)                      5         0.301       (0.199,0.454)       0.000\*        3.54    0.472    0.0    0.806                 0.911

The study of Shi [@b32] had to be excluded because it contained no individuals carrying *IL28B* rs12979860 TT genotype.

*P* for Egger\'s test could not be evaluated since there was no healthy controls carrying *IL28B* rs12979860 TT genotype in the study of Ren S[@b13].

*Abbreviations:* SNPs, single nucleotide polymorphisms. \**P*\<0.05.

We also performed stratified analyses for Asian and hospital-based individuals, and the results were still stable ([***Table 3***](#t03){ref-type="table"}). Caucasian and population-based subgroup analyses were not conducted because only 1 or 2 studies were available. Interestingly, for the comparison of *ERα* rs2077647 TT *vs.* TC+CC, significantly increased risks were observed in the Asian and hospital-based population (Asian subgroup, TT *vs.* TC+CC: OR, 1.778; 95% CI, \[1.004, 3.149\]; *P*  =  0.048; hospital-based subgroup, TT *vs.* TC+CC: OR, 2.204; 95% CI, \[1.140, 4.264\]; *P*  =  0.019), but not in the overall analysis.

###### Stratified analyses of *IFN-γ* rs2430561, *IL28B* rs12979860 and *ERα* rs2077647 polymorphisms on the outcomes of HBV infection

                                                                                                                           SNPs          Subgroups                                                           Comparison                                                            n      OR (95% CI)     Homogeneity                             
  ----------------------------------------------------------------------------------------------------------------- ------------------- ------------ -------------------------------------------------------------------------------------------------------------------------- ------- --------------- --------------- --------- ------- ------- ------
  Susceptibility to persistent infection of HBV (persistent HBV infection cases *vs.* healthy controls)              *IFN-γ* rs2430561     Asian                                                                T/A                                                                3         0.558       (0.407,0.764)   0.000\*   4.28    0.117   53.3
                                                                                                                         Hospital           T/A                                                                  3                                                               0.603   (0.388,0.937)      0.024\*       6.64     0.036   69.9   
  *IL28B* rs12979860                                                                                                       Asian            C/T                                                                  3                                                               0.416   (0.114,1.516)       0.184        8.31     0.016   75.9   
                                                                                                                                         CC/(CT+TT)                                                              4                                                               0.672   (0.364,1.240)       0.204        6.87     0.076   56.3   
                                                                                                                         Hospital        CC/(CT+TT)                                                              3                                                               0.447   (0.137,1.462)       0.183        5.90     0.052   66.1   
  *ERα* rs2077647                                                                                                          Asian            T/C                                                                  4                                                               1.822   (1.338,2.480)      0.000\*       6.74     0.081   55.5   
                                                                                                                           Asian           TT/ CC                                                                4                                                               4.402   (2.775,6.984)      0.000\*       0.49     0.921    0.0   
                                                                                                                           Asian         TT/(TC+CC)                                                              4                                                               1.778   (1.004,3.149)      0.048\*       11.63    0.009   74.2   
                                                                                                                           Asian         CC/(TT+TC)                                                              4                                                               0.287   (0.189,0.435)      0.000\*       2.27     0.519    0.0   
                                                                                                                         Hospital           T/C                                                                  3                                                               1.894   (1.156,3.102)      0.011\*       5.49     0.064   63.6   
                                                                                                                         Hospital          TT/ CC                                                                3                                                               3.838   (2.192,6.721)      0.000\*       2.28     0.319   12.5   
                                                                                                                         Hospital        TT/(TC+CC)                                                              3                                                               2.204   (1.140,4.264)      0.019\*       4.69     0.096   57.4   
                                                                                                                         Hospital        CC/(TT+TC)                                                              3                                                               0.387   (0.234,0.640)      0.000\*       1.10     0.577    0.0   
  Clearance of HBV (persistent HBV infection cases *vs.* self-limiting controls) [a](#nt108){ref-type="table-fn"}    *IFN-γ* rs2430561     Asian      Since all the studies were from Asian and hospital-based,the results were the same as [Table 3](#t03){ref-type="table"}.                                                                    
                                                                                                                         Hospital                                                                                                                                                                                                                 
  *IL28B* rs12979860                                                                                                       Asian         CC/(CT+TT)                                                              3                                                               0.809   (0.571,1.145)       0.231        0.35     0.838    0.0   
                                                                                                                         Hospital        CC/(CT+TT)                                                              3                                                               1.067   (0.713,1.596)       0.754        2.12     0.346    5.9   

Analysis of *ERα* rs2077647 T/C was not conducted to explore the association with HBV clearance because there was only one study[@b19] available. \**P*\<0.05.

SNPs: single nucleotide polymorphisms.

Association of individual polymorphisms with HBV clearance {#s3c}
----------------------------------------------------------

We also compared persistent HBV infection cases with self-limiting infection controls to discover the relationship between the three target SNPs and HBV infection clearance. As shown in [***Table 4***](#t04){ref-type="table"}, the meta-analysis provided estimated odds ratios and *P*-value of all comparison models, but only *IFN-γ* rs2430561 TT *vs.* AA showed significant difference (TT *vs.* AA: OR, 0.555; 95% CI, \[0.359, 0.856\]; *P*  =  0.008) ([***Fig. 2B***](#f02){ref-type="fig"}), indicating that carriers of *IFN-γ* rs2430561 TT genotype were more likely to clear HBV spontaneously compared with those carrying AA genotype, and there was no significant correlation of *IL28B* rs12979860 C/T polymorphism with HBV clearance. We did not conduct meta-analysis of *ERα* rs2077647 T/C because only 1 study[@b19] was available.

###### Quantitative data synthesis of individual polymorphisms, persistent hepatitis B virus infection cases versus self-limiting infection controls[a](#nt106){ref-type="table-fn"}

  SNPs          Comparison   n   OR (95% CI)    Homogeneity    Publication bias                                 
  ------------ ------------ --- ------------- --------------- ------------------ ------- ------- ------ ------- -------
  *IFN-γ*          T/A       5      0.779      (0.524,1.159)        0.218         23.53   0.000   83.0   0.806   0.390
  rs2430561       TT/AA      5      0.555      (0.359,0.856)       0.008\*        5.76    0.218   30.6   1.000   0.717
                TT/(TA+AA)   5      0.691      (0.466,1.024)        0.066         1.99    0.738   0.0    1.000   0.944
                AA/(TA+TT)   5      1.401      (0.839,2.339)        0.197         25.21   0.000   84.1   0.221   0.389
  *IL28B*          C/T       4      1.060      (0.873,1.288)        0.557         2.37    0.499   0.0    0.734   0.633
  rs12979860      CC/TT      3      1.092      (0.700,1.704)        0.697         1.49    0.475   0.0    1.000   0.855
                CC/(CT+TT)   5      1.009      (0.804,1.267)        0.937         4.21    0.378   5.0    0.462   0.346
                TT/(CC+CT)   3      0.996      (0.653,1.518)        0.984         1.20    0.549   0.0    1.000   0.395

Analysis of *ERα* rs2077647 T/C was not conducted in this table because there was only one study[@b19] available. \**P*\<0.05.

SNPs: single nucleotide polymorphisms.

In subgroup analysis of SNP *IFN-γ* rs2430561, since all the studies were from Asian and hospital-based, and the results were the same as in [***Table 3***](#t03){ref-type="table"}. Moreover, for *IL28B* rs12979860 C/T polymorphism, the results of subgroup analyses were similar to those of overall analyses. Namely, no significant association of *IL28B* rs12979860 C/T polymorphism with HBV clearance was observed in both overall analysis and stratified analysis.

Sensitivity analysis {#s3d}
--------------------

There were 4 studies[@b10],[@b11],[@b13],[@b19] not in HWE within our included studies. In the sensitivity analysis, the influence of these 4 studies on the pooled OR was examined by repeating the meta-analysis while omitting each of them, one at a time. When excluded the 4 studies mentioned above, most of the estimated pooled OR did not change at all. However, when the study by Zhang et al.[@b11] was omitted, the result of *IFN-γ* rs2430561 T *vs.* A model showed no significant association with susceptibility to persistent HBV infection. Furthermore, for *IFN-γ* rs2430561 TT *vs.* AA model, no significance was observed on the clearance of HBV when the study was excluded[@b10].

Tests of heterogeneity and publication bias {#s3e}
-------------------------------------------

Q-statistic and I^2^ statistic were used to evaluate the statistical heterogeneity and several comparison models were found to have heterogeneities ([***Table 2***](#t02){ref-type="table"} and [***Table 4***](#t04){ref-type="table"}). Thus, a random-effects model was employed in these studies. Begg\'s funnel plot and Egger\'s test were performed to assess the publication bias of the studies ([***Table 2***](#t02){ref-type="table"} and [***Table 4***](#t04){ref-type="table"}). As a result, no evidence of publication bias was found in all comparison models.

Discussion {#s3f}
----------

It is well known that the elimination of HBV is attributed to a coordinated innate and adaptive humoral and cell-mediated immune response. During this immune process, cytokines play a crucial role in modulating almost all phases of host immune response. Genetic polymorphisms of the cytokines and factors regulating cytokines may influence the expression of cytokines, thus determining the various clinical outcomes of HBV infection.

As one of the most representative Th1 cytokines, *IFN-γ* plays an important role in the clearance of HBV. On one hand, in acute self-limited HBV infection, the antigen-specific fraction of T cells selectively secrete Th1-type cytokines, with a predominance of *IFN-γ*[@b23]. On the other hand, cell clones from persons with chronic HBV infection produce a predominantly type 2 response[@b24]. *IFN-γ* rs2430561T/A is a SNP located in the first intron of the *IFN-γ* gene, which is confirmed to coincide with the nuclear factor-κB (NF-κB) binding region[@b25]. It had been demonstrated that possession of rs2430561T and A alleles should be associated with high and low *IFN-γ* expression, respectively[@b7],[@b25]. In this study, we performed a meta-analysis and concluded that *IFN-γ* rs2430561 T allele was associated with significantly reduced risk of persistent HBV infection and the carriers with the *IFN-γ* rs2430561 TT genotype were more likely to clear HBV spontaneously compared with those carrying the *IFN-γ* rs2430561 AA genotype. In stratified analyses, the results did not change in Asian and hospital-based subgroups. However, when studies not in HWE were excluded, the results showed no significance. Nevertheless, it was still meaningful that *IFN-γ* rs2430561 T allele and TT genotype could up-regulate the expression of *IFN-γ*, rendering these subjects less prone to persistent HBV infection. Most importantly, more functional analyses should be conducted to demonstrate it.

This meta-analysis documented that the SNP 4 kilobases upstream of *IL28B* (rs12979860) was not associated with outcomes of HBV infection. However, prior studies had shown that this SNP correlated with both spontaneous and anti-viral treatment-induced HCV clearance[@b26],[@b27]. These conflicting results suggested that although HBV and HCV shared a similar natural history, pathogenesis and transmission modality[@b28], rs12979860 might alter the immune responses against HCV but not HBV. Potentially, this could be explained by the characteristics of *IL28B*. By triggering a cascade through the JAK-STAT (Janus kinase-signal transducer and activator of transcription, JAK-STAT) pathway, *IL28B* up-regulates the IFN-stimulated genes (*ISGs*) and produces an antiviral state[@b29]. In addition, when used as a vaccine adjuvant, *IL28B* could significantly decrease splenic regulatory T cells, increase splenic and peripheral blood CD8+ T cells, and lead to increased antigen-specific perforin induction and degranulation[@b30]. These adaptive immune responses might be more important in HCV infection[@b15]. Therefore, *IL28B* plays a more important role in the infection of HCV than that of HBV.

Chronic hepatitis B progresses at unequal rates between males and females, being more frequent in men than in women[@b31]. This sexual dimorphism might be due to lower expression of estrogen and a reduced response to the action of estrogen[@b32]. Furthermore, It was reported that estrogen could directly activate the promoter of *IFN-γ* and this effect was mediated by estrogen receptors (ERs, *ERα* and ERβ)[@b16]. The production and function of ER might be influenced by its own variation, and thus influence the diverse pathologies of chronic hepatopathy[@b17],[@b18]. According to our findings, compared to CT+TT, *ERα* rs2077647 CC genotype might play a role in protecting individuals against HBV persistence, since the risk of persistent HBV infection was reduced to 0.289 (95% CI, \[0.187, 0.446\]; *P* \< 0.001). However, *ERα* rs2077647 T/C is a synonymous polymorphism located in exon 1, and Zhai et al.[@b22] investigated that such effect could be caused by some other functional polymorphisms (such as a \[TA\]n repeat and a PvuII RFLP) in LD with rs2077647 T/C. Thus, to date, the potential function of rs2077647 T/C could not be confirmed, and further investigation was required to explore the exact mechanism and association of *ERα* polymorphisms with outcomes of HBV infection.

It should be noted that there were certain limitations to our study. Firstly, due to the limited availability of published results, the number of studies included in each meta-analysis was small. We expected that as more studies become available, an accurate estimation of the relationship of the 3 SNPs with susceptibility and clearance to persistence HBV infection would be obtained. Secondly, several comparison models were found to have heterogeneities, and the genotype distribution also showed deviation from HWE in four studies. These could be attributed to ethnic differences (Asian versus non-Asian descent), potential selection bias (in-patients versus outpatients) or other factors. The third limitation of this analysis is that we did not have original data for all studies to account for other factors, like presence of co-infection with HIV or immune deficiency, genotypes of HBV and transmission modality that may modify the risk estimates. In spite of these, meta-analysis is a powerful statistical tool to summarize inconsistent results from different studies, so our meta-analysis provided more convincing conclusions.

In summary, this meta-analysis suggested that *IFN-γ* rs2430561 T/A and *ERα* rs2077647 T/C genetic polymorphisms were associated with the outcomes of HBV infection, but association between *IL28B* rs12979860 C/T and HBV infection was not found. Since limitations were present in our study, it is critical that lager and well-designed multicenter studies should be performed to re-evaluate the associations. Moreover, further studies incorporating diverse populations and functional assays are warranted to validate and extend our findings.
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